Posting Date: July 27, 2022

Closing Date: August 8, 2022

Reference Number: 22-047500

To: NCI Bid Board

From: Jennifer Mothershead
NCI P-ARC Purchasing Agent
mothersj@mail.nih.gov

Subject: NCI Bid Board Posting – The purpose of this acquisition is to solicit a Benchtop, Automated Tissue Dissociator.

The National Cancer Institute (NCI), Experimental Immunology Branch (EIB), A. Singer lab is currently studying lymphocyte in nonlymphoid tissues during autoimmune disease. This benchtop machine will be instrumental in examining the crosstalk between innate and adaptive immune system in nonlymphoid tissues during the development of autoimmune disease in mice model. This process will be beneficial to therapeutical applications in human autoimmune patients.

The National Cancer Institute, Experimental Immunology Branch (EIB) plans to procure a Benchtop, Automated Tissue Dissociator This is not a request for competitive quotation. However, if any interested party believes it can meet the attached requirements, it may submit a statement of capabilities. The capability statement must be in writing and must contain information and material in sufficient detail to allow NCI to determine is the party can fully meet this requirement. The capability statement must be received in the contracting office by 11:30 AM on August 8, 2021 ET. A determination by the Government not to compete this requirement based upon responses to this notice is solely within the discretion of the Government. Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement.

Sole Source Justification:

Attached Documents:
SF18

FAR Clause 52.213-4 Simplified Acquisitions Terms and Conditions (AUG 2019) is applicable and available in full text upon request